Affordable oral proinsulin bioencapsulated in plant cells regulates blood sugar levels similar to natural insulin

Loading...
Thumbnail Image
Penn collection
School of Dental Medicine::Departmental Papers (Dental)
Degree type
Discipline
Dentistry
Subject
C-peptide
Cold-chain free
Oral delivery
Plant cell bioencapsulation
Proinsulin
Funder
Grant number
Copyright date
2023-07
Distributor
Related resources
Author
Daniell, Henry
Singh, Rahul
Mangu, Venkata
Nair, Smruti K.
Wakade, Geetanjali
Balashova, Nataliya
Contributor
Abstract

Diabetes Mellitus is a silent epidemic affecting >500 million, which claimed 6.7 million lives in 2021, a projected increase of >670% in <20 years old in the next two decades but insulin is unaffordable for the large majority of the globe. Therefore, we engineered proinsulin in plant cells to facilitate oral delivery. Stability of the proinsulin gene and expression in subsequent generations, after removal of the antibiotic-resistance gene, was confirmed using PCR, Southern and western blots. Proinsulin expression was high (up to 12 mg/g DW or 47.5% of total leaf protein), stable up to one year after storage of freeze-dried plant cells at ambient temperature and met FDA regulatory requirements of uniformity, moisture content and bioburden. GM1 receptor binding, required for uptake via gut epithelial cells was confirmed by pentameric assembly of CTB-Proinsulin. IP insulin injections (without C peptide) in STZ mice rapidly decreased blood glucose level leading to transient hypoglycemia, followed by hepatic glucose compensation. On the other hand, other than the 15-min lag period of oral proinsulin (transit time required to reach the gut), the kinetics of blood sugar regulation of oral CTB-Proinsulin in STZ mice was very similar to naturally secreted insulin in healthy mice (both contain C-peptide), without rapid decrease or hypoglycemia. Elimination of expensive fermentation, purification and cold storage/transportation should reduce cost and increase other health benefits of plant fibers. The recent approval of plant cell delivery of therapeutic proteins by FDA and approval of CTB-ACE2 for phase I/II human clinical studies augur well for advancing oral proinsulin to the clinic. © 2023 The Authors

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2023-07
Journal title
Biomaterials
Volume number
Issue number
Publisher
Elsevier
Publisher DOI
10.1016/j.biomaterials.2023.122142
Journal Issue
Comments
Recommended citation
Collection